Novartis pays $310 million upfront for inflammation specialist IFM

Novartis on Monday said it had agreed to pay $310 million upfront, with the possibility for more later, for some assets of Boston-based inflammation specialist IFM Therapeutics as the Swiss drugmaker seeks to expand its immunology pipeline.

from Reuters: Business News https://ift.tt/2HR4ibc